Literature DB >> 2852915

Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis.

D L Taylor1, L E Fellows, G H Farrar, R J Nash, D Taylor-Robinson, M A Mobberley, T A Ryder, D J Jeffries, A S Tyms.   

Abstract

Many plants contain polyhydroxyalkaloids which are potent inhibitors of glucosidases, enzymes involved in oligosaccharide trimming. These are important in determining the final configuration of specific glycoproteins. Human cytomegalovirus (CMV) encodes a number of glycoproteins, some of which ultimately reside in the outer envelope of the mature virion and are important for virus infectivity. Treatment with three polyhydroxyalkaloids, castanospermine (CAST), deoxynojirimycin (DNJ) and 2R,5R-dihydroxymethyl-3R,4R-dihydroxypyrrolidine (DMDP) blocked the growth of infectious virus, as determined by yield reduction and plaque reduction assays. However, in the presence of CAST, CMV infected cells continued to shed virions into the extracellular medium, as determined by electron microscopy. Envelope glycoproteins of virions produced after treatment with CAST (2.5 mM) were immunoprecipitated with a monoclonal antibody (F5) specific for the gcI family of glycoproteins. Analysis by PAGE-SDS showed an absence of gcI complex 2 (gp52 disulphide-linked to gp130) with a proportional increase in gcI complex 1 (gp52 disulphide-linked to gp95). The results indicated that gp130 alone, or linked to gp52, was important for CMV infectivity. As well as being potential targets for antiviral agents against CMV, inhibitors of glycoprotein trimming reactions may define components of the virion surface important for infectivity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852915      PMCID: PMC7134106          DOI: 10.1016/0166-3542(88)90011-3

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  41 in total

1.  Characterization of a human cytomegalovirus glycoprotein complex (gcI).

Authors:  D R Gretch; R C Gehrz; M F Stinski
Journal:  J Gen Virol       Date:  1988-06       Impact factor: 3.891

2.  Characterization of the human cytomegalovirus envelope glycoproteins.

Authors:  G H Farrar; J D Oram
Journal:  J Gen Virol       Date:  1984-11       Impact factor: 3.891

3.  Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections.

Authors:  S Stagno; D W Reynolds; A Tsiantos; D A Fuccillo; W Long; C A Alford
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

4.  Polyamine metabolism in MRC-5 cells infected with human cytomegalovirus.

Authors:  A S Tyms; J D Williamson
Journal:  J Gen Virol       Date:  1980-05       Impact factor: 3.891

5.  Successful treatment of human genital herpes infections with 2-deoxy-D-glucose.

Authors:  H A Blough; R L Giuntoli
Journal:  JAMA       Date:  1979-06-29       Impact factor: 56.272

Review 6.  Cytomegalovirus and the acquired immunodeficiency syndrome.

Authors:  A S Tyms; D L Taylor; J M Parkin
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

7.  The pyrrolidine alkaloid, 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine, inhibits glycoprotein processing.

Authors:  A D Elbein; M Mitchell; B A Sanford; L E Fellows; S V Evans
Journal:  J Biol Chem       Date:  1984-10-25       Impact factor: 5.157

8.  Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus.

Authors:  L E Rasmussen; R M Nelson; D C Kelsall; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

9.  Suppression of glycoprotein formation of Semliki Forest, influenza, and avian sarcoma virus by tunicamycin.

Authors:  R T Schwarz; J M Rohrschneider; M F Schmidt
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

10.  Inhibition of N-linked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases.

Authors:  B Saunier; R D Kilker; J S Tkacz; A Quaroni; A Herscovics
Journal:  J Biol Chem       Date:  1982-12-10       Impact factor: 5.157

View more
  6 in total

1.  Antiviral effects of an iminosugar derivative on flavivirus infections.

Authors:  Shu-Fen Wu; Chyan-Jang Lee; Ching-Len Liao; Raymond A Dwek; Nicole Zitzmann; Yi-Ling Lin
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.

Authors:  Xuesen Zhao; Fang Guo; Mary Ann Comunale; Anand Mehta; Mohit Sehgal; Pooja Jain; Andrea Cuconati; Hanxin Lin; Timothy M Block; Jinhong Chang; Ju-Tao Guo
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  Analysis of human antibody responses to human cytomegalovirus envelope glycoproteins found in two families of disulfide linked glycoprotein complexes designated gC-I and gC-II.

Authors:  B Kari; R Gehrz
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 4.  Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents.

Authors:  Jinhong Chang; Ju-Tao Guo; Yanming Du; Timothy Block
Journal:  Emerg Microbes Infect       Date:  2013-11-20       Impact factor: 7.163

Review 5.  Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus.

Authors:  Joanna L Miller; Beatrice E Tyrrell; Nicole Zitzmann
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

Review 6.  Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions.

Authors:  Jinhong Chang; Timothy M Block; Ju-Tao Guo
Journal:  Antiviral Res       Date:  2013-06-29       Impact factor: 5.970

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.